Literature DB >> 31441171

High-resolution structural analysis shows how different crystallographic environments can induce alternative modes of binding of a phosphotyrosine peptide to the SH2 domain of Fer tyrosine kinase.

Yoshiyuki Matsuura1,2.   

Abstract

Fes and Fes-related (Fer) protein tyrosine kinases (PTKs) comprise a subfamily of nonreceptor tyrosine kinases characterized by a unique multidomain structure composed of an N-terminal Fer/CIP4 homology-Bin/Amphiphysin/Rvs (F-BAR) domain, a central Src homology 2 (SH2) domain, and a C-terminal PTK domain. Fer is ubiquitously expressed, and upregulation of Fer has been implicated in various human cancers. The PTK activity of Fes has been shown to be positively regulated by the binding of phosphotyrosine-containing ligands to the SH2 domain. Here, the X-ray crystal structure of human Fer SH2 domain bound to a phosphopeptide that has D-E-pY-E-N-V-D sequence is reported at 1.37 å resolution. The asymmetric unit (ASU) contains six Fer-phosphopeptide complexes, and the structure reveals three distinct binding modes for the same phosphopeptide. At four out of the six binding sites in the ASU, the phosphopeptide binds to Fer SH2 domain in a type I β-turn conformation, and this could be the optimal binding mode of this phosphopeptide. At the other two binding sites in the ASU, it appears that spatial proximity of neighboring SH2 domains in the crystal induces alternative modes of binding of this phosphopeptide.
© 2019 The Protein Society.

Entities:  

Keywords:  Fer; SH2 domain; ligand recognition; phosphorylation; tyrosine kinase

Mesh:

Substances:

Year:  2019        PMID: 31441171      PMCID: PMC6798132          DOI: 10.1002/pro.3713

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  47 in total

Review 1.  Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems.

Authors:  Tony Pawson
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

2.  Molecular replacement with MOLREP.

Authors:  Alexei Vagin; Alexei Teplyakov
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-12-21

3.  A noncatalytic domain conserved among cytoplasmic protein-tyrosine kinases modifies the kinase function and transforming activity of Fujinami sarcoma virus P130gag-fps.

Authors:  I Sadowski; J C Stone; T Pawson
Journal:  Mol Cell Biol       Date:  1986-12       Impact factor: 4.272

4.  Identification of Fer tyrosine kinase localized on microtubules as a platelet endothelial cell adhesion molecule-1 phosphorylating kinase in vascular endothelial cells.

Authors:  Naoko Kogata; Michitaka Masuda; Yuji Kamioka; Akiko Yamagishi; Akira Endo; Masato Okada; Naoki Mochizuki
Journal:  Mol Biol Cell       Date:  2003-06-13       Impact factor: 4.138

5.  Defining the specificity space of the human SRC homology 2 domain.

Authors:  Haiming Huang; Lei Li; Chenggang Wu; David Schibli; Karen Colwill; Sucan Ma; Chengjun Li; Protiva Roy; Krystina Ho; Zhou Songyang; Tony Pawson; Youhe Gao; Shawn S-C Li
Journal:  Mol Cell Proteomics       Date:  2007-10-22       Impact factor: 5.911

6.  Conformational determinants of phosphotyrosine peptides complexed with the Src SH2 domain.

Authors:  Joseph Nachman; Gerry Gish; Cristina Virag; Tony Pawson; Régis Pomès; Emil Pai
Journal:  PLoS One       Date:  2010-06-21       Impact factor: 3.240

7.  Overview of the CCP4 suite and current developments.

Authors:  Martyn D Winn; Charles C Ballard; Kevin D Cowtan; Eleanor J Dodson; Paul Emsley; Phil R Evans; Ronan M Keegan; Eugene B Krissinel; Andrew G W Leslie; Airlie McCoy; Stuart J McNicholas; Garib N Murshudov; Navraj S Pannu; Elizabeth A Potterton; Harold R Powell; Randy J Read; Alexei Vagin; Keith S Wilson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-03-18

8.  Targeting FER Kinase Inhibits Melanoma Growth and Metastasis.

Authors:  Iordanka A Ivanova; Shinthujah Arulanantham; Kevin Barr; Mario Cepeda; Katie M Parkins; Amanda M Hamilton; Danielle Johnston; Silvia Penuela; David A Hess; John A Ronald; Lina Dagnino
Journal:  Cancers (Basel)       Date:  2019-03-24       Impact factor: 6.639

9.  High expression of FER tyrosine kinase predicts poor prognosis in clear cell renal cell carcinoma.

Authors:  Can Wei; Song Wu; Xianxin Li; Yadong Wang; Rui Ren; Yongqing Lai; Jiongxian Ye
Journal:  Oncol Lett       Date:  2012-11-16       Impact factor: 2.967

10.  FER kinase promotes breast cancer metastasis by regulating α6- and β1-integrin-dependent cell adhesion and anoikis resistance.

Authors:  I A Ivanova; J F Vermeulen; C Ercan; J M Houthuijzen; F A Saig; E J Vlug; E van der Wall; P J van Diest; M Vooijs; P W B Derksen
Journal:  Oncogene       Date:  2013-07-22       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.